Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($3.61) EPS for the quarter, topping the Zacks' consensus estimate of ($4.27) by $0.66. The company had revenue of $21 million for the quarter, compared to analysts' expectations of $15.88 million. Intercept Pharmaceuticals had a negative return on equity of 116.30% and a negative net margin of 825.58%. The firm's quarterly revenue was up 4566.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($5.17) earnings per share. View Intercept Pharmaceuticals' Earnings History.

15 equities research analysts have issued 1-year price objectives for Intercept Pharmaceuticals' stock. Their forecasts range from $60.00 to $350.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $197.46 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

• 1. Cowen and Company analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)
• 2. According to Zacks Investment Research, "Intercept’s first-quarter results were encouraging as the company reported a narrower-than-expected loss and beat on revenues. Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry so far in 2017." (5/8/2017)
• 3. BMO Capital Markets analysts commented, "We are raising our PT to $221 from $198 as we believe updated launch metrics suggest continued steady uptake of Ocaliva for PBC driven by greater physician awareness and more open access, supporting our above-consensus 2017 sales estimates. We believe the removal of the REGENERATE enrollment overhang could allow ICPT shares to trade up meaningfully on any signs of efficacy in PSC Ph2 as it remains a source of upside to our and Street estimates. We expect Ocaliva sales growth and development milestones to help ICPT shares recover." (2/24/2017)
• 4. Wedbush analysts commented, "We believe several clinical catalysts later this year could provide upside to ICPT's current price. Q4/FY:16 Financials: Q4/FY:16 Ocaliva sales were $13.4MM/$18.2MM. Revenues of $13.8MM/$24.9MM also came in higher than consensus estimates of $8.96MM/$20.16MM. GAAP (loss) of $(4.84)/$16.74) came in lower than consensus estimates of $(3.68)/($15.63) on higher than expected SG&A expenses. We have incorporated Q4/FY:16 financials and updated our model based on 2017 guidance. ICPT ended 2016 with cash balance of $689.4MM. Progress on the Ocaliva launch. ICPT appears to be making significant progress with reimbursement, with the time to filled-prescription now at three weeks." (2/24/2017)
• 5. Needham & Company LLC analysts commented, "Intercept reported 4Q16 financial results today. Ocaliva sales were $13.4M, compared to our $9.0M and consensus $7.8M est. Mgmt cited better than expected gross:net. No sales guidance was issued, as expected, although mgmt indicated 1Q17 sales will only be modestly above 4Q16, w/ expectations for gross:net to worsen. As a reminder, drug was launched in Jun 2016 for treatment of PBC. Ocaliva launch is progressing well, but we believe this is already factored in stock. Mgmt recently negotiated changes to Phase 3 REGENERATE NASH trial design, allowing for smaller pt population. We expect a favorable outcome, but note results will still not be available until 1H19." (2/23/2017)

Some companies that are related to Intercept Pharmaceuticals include Kite Pharma (KITE), Clovis Oncology (CLVS), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC (GWPH), Axovant Sciences (AXON), AveXis (AVXS), Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), Radius Health (RDUS), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Sarepta Therapeutics (SRPT) and Aerie Pharmaceuticals (AERI).

Intercept Pharmaceuticals' management team includes the folowing people:

• Paolo Fundaro, Independent Chairman of the Board
• Mark Pruzanski M.D., President, Chief Executive Officer, Director
• Sandip S. Kapadia, Chief Financial Officer, Treasurer
• Lisa Bright, President, International
• Jerome Benedict Durso, Chief Operating Officer
• David Ford, Chief Human Resource Officer
• David M. Shapiro M.D., Chief Medical Officer, Executive Vice President - Development
• Richard Kim, Senior Vice President, Commercial U.S.
• Rachel L. McMinn Ph.D., Chief Business and Strategy Officer
• Srinivas Akkaraju M.D. Ph.D., Independent Director

Intercept Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (5.12%), State Street Corp (3.24%), BB Biotech AG (1.03%), First Trust Advisors LP (0.99%) and Macquarie Group Ltd. (0.97%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, David Shapiro, Klaus R Dr Veitinger, Lisa Bright, Luciano Adorini, Mark Pruzanski, Nicole Williams and Rachel Mcminn. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Marshall Wace LLP, First Trust Advisors LP, ING Groep NV, KCG Holdings Inc., State of Wisconsin Investment Board, ProShare Advisors LLC and AXA. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, David Shapiro, Lisa Bright, Mark Pruzanski and Rachel Mcminn. View Insider Buying and Selling for Intercept Pharmaceuticals.

Intercept Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Macquarie Group Ltd., Vanguard Group Inc., State Street Corp, Point72 Asset Management L.P., Geode Capital Management LLC and Sphera Funds Management LTD.. View Insider Buying and Selling for Intercept Pharmaceuticals.

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $122.99.